Therosteon

Luciano Adorini

Luciano is the CSO of Intercept pharma from New York. Previously he was CSO of Bioxell, a successful biotech start-up in Milan (It) that was spun-off from Roche.

Roland Baron

Roland is Professor Internal Medicine, Harvard Medical School. Previously he worked at Yale University and was the CEO of a biotechnology company in the area of bone diseases: Proskelia. Proskelia was a spin-off from Aventis Pharma, which merged with Prostrachan in 2004.

Huib Pols

Huibert is the dean of the Erasmus Medical School in Rotterdam. He is a world renowned expert in the field of bone diseases and the author of numerous papers in the field.